Literature DB >> 3917276

OKT3 monoclonal antibody induces production of colony-stimulating factor(s) for granulocytes and macrophages in cultures of human T lymphocytes and adherent cells.

E Platzer, B Y Rubin, L Lu, K Welte, H E Broxmeyer, M A Moore.   

Abstract

OKT3 monoclonal antibody (mab) recognizes a membrane antigen associated with the T cell antigen recognition receptor, and is known to be mitogenic and to induce lymphokine production. Our studies demonstrate the ability of OKT3 mab to induce from cultures of human T lymphocytes supplemented with adherent cells the production of colony-stimulating factor(s) for granulocytes and macrophages (GM-CSF) and interferon-gamma (IFN-gamma), an inhibitor of clonal growth of hematopoietic progenitor cells. As has been shown for the mitogenic and IFN-gamma-inducing activity of OKT3 mab, the induction of GM-CSF release in cultures of T cells is strictly dependent on the presence of adherent cells. However, the concentrations of OKT3 mab required for optimal GM-CSF production (50 ng/ml) were found to be 80-fold higher than those sufficient for maximal IFN-gamma production, proliferation, and interleukin 2 production. IFN-gamma activity induced by OKT3 mab partially inhibited colony and cluster formation from progenitor cells of granulocytes and macrophages in vitro. Therefore, neutralization of the IFN-gamma by monoclonal anti-human-IFN-gamma antibody before assay of conditioned medium in bone marrow cultures significantly enhanced the detection of GM-CSF. Kinetic studies demonstrated maximal cumulative GM-CSF production in response to optimal OKT3 mab concentrations on days 4 through 6 in cultures of T cells supplemented with 15% adherent cells. Highly enriched OKT4+ and OKT8+ T cell subsets co-cultured with adherent cells in the presence of OKT3 mab both produced GM-CSF and IFN-gamma and showed similar dose-response curves to OKT3 mab. The requirement for the presence of adherent cells could not be overcome by the addition of purified interleukin 1 or macrophage supernatants. Studies using irreversible inhibitors of DNA (mitomycin C) or protein biosynthesis (emetine-HCl) revealed the necessity of intact DNA synthesis and translation in mononuclear cells to produce GM-CSF in response to OKT3 mab. Loss of GM-CSF production was observed when either adherent cells or T lymphocytes were treated with emetine before co-culture with untreated cells of the other population in the presence of OKT3 mab. In contrast, mitomycin C reduced GM-CSF production significantly when T cells, but not adherent cells, were pretreated. These results suggest that T lymphocytes and adherent cells closely cooperate in the production of GM-CSF induced by OKT3 mab.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3917276

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  Regulation of colony-stimulating factor production by normal and leukemic human cells.

Authors:  T J Ernst; J D Griffin
Journal:  Immunol Res       Date:  1989       Impact factor: 2.829

2.  Eosinophil differentiating activity in sera of patients with AIDS under recombinant IL-2 substitution.

Authors:  P Kern; M Dietrich
Journal:  Blut       Date:  1986-04

3.  A T-lymphocyte-derived factor that enhances IgG-dependent release of leukotriene B4 (LTB4) from human neutrophils.

Authors:  J J Tsai; P Maestrelli; O Cromwell; R Moqbel; P Fitzharris; A B Kay
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

4.  Role of macrophages in serum colony-stimulating factor induction by Lactobacillus casei in mice.

Authors:  M Nanno; T Shimizu; A Mike; M Ohwaki; M Mutai
Journal:  Infect Immun       Date:  1988-02       Impact factor: 3.441

5.  Biological activities of a human pluripotent hemopoietic colony stimulating factor on normal and leukemic cells.

Authors:  E Platzer; K Welte; J L Gabrilove; L Lu; P Harris; R Mertelsmann; M A Moore
Journal:  J Exp Med       Date:  1985-12-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.